Evolent Health Stock Price, News & Analysis (NYSE:EVH)

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EVH shares.
View EVH analyst ratings or view top-rated stocks.

7 equities research analysts have issued 1 year price objectives for Evolent Health's stock. Their EVH share price targets range from $34.00 to $59.00. On average, they predict the company's share price to reach $45.50 in the next twelve months. This suggests a possible upside of 63.7% from the stock's current price.
View analysts price targets for EVH or view top-rated stocks among Wall Street analysts.

Evolent Health's stock was trading at $28.08 on January 1st, 2023. Since then, EVH shares have decreased by 1.0% and is now trading at $27.79.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our EVH earnings forecast.

Evolent Health, Inc. (NYSE:EVH) released its quarterly earnings data on Thursday, November, 2nd. The technology company reported $0.19 earnings per share for the quarter. The technology company earned $511.02 million during the quarter, compared to the consensus estimate of $508.21 million. Evolent Health had a negative net margin of 5.08% and a positive trailing twelve-month return on equity of 4.83%.

ETFs with the largest weight of Evolent Health (NYSE:EVH) stock in their portfolio include Fidelity Digital Health ETF (FDHT), Harbor Corporate Culture Small Cap ETF (HAPS), Fidelity Disruptive Medicine ETF (FMED), Harbor Small Cap Explorer ETF (QWST).LeaderShares Activist Leaders ETF (ACTV) and

12 employees have rated Evolent Health Chief Executive Officer Seth Blackley on Glassdoor.com. Seth Blackley has an approval rating of 100% among the company's employees. This puts Seth Blackley in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include CA (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Advanced Micro Devices (AMD), Energy Transfer (ET), Chipotle Mexican Grill (CMG), Ford Motor (F), Cisco Systems (CSCO) and Heron Therapeutics (HRTX).

(EVH) raised $150 million in an initial public offering (IPO) on Friday, June 5th 2015. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Evolent Health's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.35%), Rock Springs Capital Management LP (3.36%), RA Capital Management L.P. (2.38%), Eventide Asset Management LLC (2.30%), William Blair Investment Management LLC (2.32%) and Loomis Sayles & Co. L P (1.81%). Insiders that own company stock include Cheryl Scott, Daniel Joseph Mccarthy, Diane Holder, Frank J Williams, Frank J Williams, John Paul Johnson, Jonathan Weinberg, Mary Bridget Duffy, Seth Blackley, Simon Maisey and Steve Tutewohl.
View institutional ownership trends.

Shares of EVH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.